Dr Shui Ki (Henry) Seto joins iVigee as Chief Medical Officer

We are thrilled to announce the appointment of Dr. Shui Ki (Henry) Seto, M.D., F.A.C.C., F.A.C.P., as iVigee's Chief Medical Officer (CMO) effective June 15, 2024. Dr. Seto brings an impressive background in pharmacovigilance, regulatory and medical affairs, and clinical development from his roles at Vertex Pharmaceuticals, Bristol-Myers Squibb, and Pfizer. His expertise in managing global safety operations and his proven leadership in innovative drug development are invaluable assets to our team and clients. His robust clinical background and strategic acumen in regulatory compliance and drug safety will be pivotal as we open a new line of services in medical safety.

Dr. Seto is a senior physician executive with exceptional medical credentials and extensive clinical practice experience. He holds a Doctorate of Medicine from Tufts University School of Medicine, completed his Internal Medicine Residency at the New England Deaconess Hospital, Harvard Medical School, and completed his Cardiovascular Disease Fellowship at Dartmouth-Hitchcock Medical Center, Dartmouth Medical School. He has held significant positions, including Vice-President of Global Patient Safety at Vertex and Vice-President of Safety Reporting at Bristol-Myers Squibb. Throughout his career, he has demonstrated excellence in strategy, change management, and operations, often pioneering new solutions that have transformed the industry.

At iVigee, we are committed to providing top-tier services, including pharmacovigilance, risk management, and regulatory compliance. Dr. Seto's appointment aligns with our mission to enhance these services and expand our capabilities in medical safety. His leadership will be instrumental in elevating our medical safety offerings and delivering unparalleled service to our clients.

In addition to his role as CMO, Dr. Seto will also join the Board of Directors of iVigee and will become President of iVigee USA.